• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.新型冠状病毒肺炎与重度哮喘中的生物制剂：来自比利时重度哮喘登记处的数据
Eur Respir J. 2020 Dec 3;56(6). doi: 10.1183/13993003.02857-2020. Print 2020 Dec.
2
Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry.重度哮喘伴鼻息肉患者对生物制剂的实际反应：来自比利时重度哮喘登记处的见解
Lung. 2024 Aug;202(4):441-448. doi: 10.1007/s00408-024-00715-0. Epub 2024 Jul 15.
3
Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry.2017 - 2022年重度哮喘患者的疾病负担与生物疗法可及性：国际重度哮喘注册研究分析
J Asthma Allergy. 2024 Oct 25;17:1055-1069. doi: 10.2147/JAA.S468068. eCollection 2024.
4
SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.严重哮喘患者接受生物制剂治疗后感染 SARS-CoV-2。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2588-2595. doi: 10.1016/j.jaip.2022.05.041. Epub 2022 Jun 23.
5
Poor outcome of SARS-CoV-2 infection in patients with severe asthma on biologic therapy.接受生物治疗的重度哮喘患者感染新型冠状病毒2的预后不良。
Respir Med. 2021 Feb;177:106287. doi: 10.1016/j.rmed.2020.106287. Epub 2020 Dec 24.
6
Real-world biologics response and super-response in the International Severe Asthma Registry cohort.真实世界生物制剂应答和超应答在国际严重哮喘注册研究队列中的表现。
Allergy. 2024 Oct;79(10):2700-2716. doi: 10.1111/all.16178. Epub 2024 Jun 22.
7
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.COVID-19 风险和结局在接受生物制剂或全身皮质类固醇治疗的成年哮喘患者中的：全国真实世界证据。
J Allergy Clin Immunol. 2021 Aug;148(2):361-367.e13. doi: 10.1016/j.jaci.2021.06.006. Epub 2021 Jun 15.
8
Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR).重度哮喘患者表型的异质性。比利时重度哮喘登记处（BSAR）。
Respir Med. 2014 Dec;108(12):1723-32. doi: 10.1016/j.rmed.2014.10.007. Epub 2014 Oct 27.
9
Guidance for Administering Biologics for Severe Asthma and Allergic Conditions.严重哮喘和过敏疾病生物制剂使用指南。
Can Respir J. 2022 Sep 10;2022:9355606. doi: 10.1155/2022/9355606. eCollection 2022.
10
Anti-IL-5/5Ra biologics improve work productivity and activity in severe asthma: a RAPSODI registry-based cohort study.抗白细胞介素-5/5 受体拮抗剂生物制剂可改善重度哮喘患者的工作生产力和活动能力：基于 RAPSODI 登记的队列研究。
J Asthma. 2023 Oct;60(10):1869-1876. doi: 10.1080/02770903.2023.2196563. Epub 2023 Apr 21.

引用本文的文献

1
COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation.接受靶向2型炎症生物药物治疗的意大利患者的COVID-19临床特征与转归
Life (Basel). 2024 Mar 13;14(3):378. doi: 10.3390/life14030378.
2
GEMA 5.3. Spanish Guideline on the Management of Asthma.GEMA 5.3. 《西班牙哮喘管理指南》。
Open Respir Arch. 2023 Sep 19;5(4):100277. doi: 10.1016/j.opresp.2023.100277. eCollection 2023 Oct-Dec.
3
Adult Severe Asthma Registries: A Global and Growing Inventory.成人重度哮喘登记处：一份全球且不断增长的清单。
Pragmat Obs Res. 2023 Oct 20;14:127-147. doi: 10.2147/POR.S399879. eCollection 2023.
4
Asthma and COVID-19: a controversial relationship.哮喘和 COVID-19：一种有争议的关系。
Virol J. 2023 Sep 7;20(1):207. doi: 10.1186/s12985-023-02174-0.
5
Coronavirus Disease 2019 Vaccine-Induced Flare-Up of Severe Bronchial Asthma Previously Controlled With Dupilumab: A Case Report.2019冠状病毒病疫苗诱发曾用度普利尤单抗控制的重度支气管哮喘发作：一例报告
Cureus. 2023 Apr 25;15(4):e38122. doi: 10.7759/cureus.38122. eCollection 2023 Apr.
6
Roles of real-world evidence in severe asthma treatment: challenges and opportunities.真实世界证据在重度哮喘治疗中的作用：挑战与机遇。
ERJ Open Res. 2023 Apr 11;9(2). doi: 10.1183/23120541.00248-2022. eCollection 2023 Mar.
7
Omalizumab may protect allergic patients against COVID-19: A systematic review.奥马珠单抗可能保护过敏患者预防新型冠状病毒肺炎：一项系统评价。
World Allergy Organ J. 2023 Feb;16(2):100741. doi: 10.1016/j.waojou.2023.100741. Epub 2023 Jan 9.
8
Recent advances in understanding the role of eosinophils.嗜酸性粒细胞作用认识的最新进展。
Fac Rev. 2022 Sep 27;11:26. doi: 10.12703/r/11-26. eCollection 2022.
9
The Incidence and Severity of COVID-19 in the Liverpool Severe Asthma Population Undergoing Biologic Therapy.接受生物治疗的利物浦重症哮喘患者中新冠病毒病的发病率和严重程度
Cureus. 2022 Sep 5;14(9):e28790. doi: 10.7759/cureus.28790. eCollection 2022 Sep.
10
SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.严重哮喘患者接受生物制剂治疗后感染 SARS-CoV-2。
J Allergy Clin Immunol Pract. 2022 Oct;10(10):2588-2595. doi: 10.1016/j.jaip.2022.05.041. Epub 2022 Jun 23.

本文引用的文献

1
Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation.需要住院的 COVID-19 肺炎合并哮喘患者的特征和结局。
Eur Respir J. 2020 Nov 5;56(5). doi: 10.1183/13993003.01875-2020. Print 2020 Nov.
2
Reply to Lipworth : Inhaled Corticosteroids and COVID-19.对利普沃思的回复：吸入性糖皮质激素与2019冠状病毒病
Am J Respir Crit Care Med. 2020 Sep 15;202(6):900-902. doi: 10.1164/rccm.202006-2129LE.
3
Factors associated with COVID-19-related death using OpenSAFELY.使用 OpenSAFELY 分析与 COVID-19 相关死亡的因素。
Nature. 2020 Aug;584(7821):430-436. doi: 10.1038/s41586-020-2521-4. Epub 2020 Jul 8.
4
Eosinopenia as an early diagnostic marker of COVID-19 at the time of the epidemic.嗜酸性粒细胞减少作为疫情期间新冠病毒病的早期诊断标志物。
EClinicalMedicine. 2020 Jun 18;23:100398. doi: 10.1016/j.eclinm.2020.100398. eCollection 2020 Jun.
5
Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19.COVID-19 住院和非住院患者中哮喘的患病率和特征。
J Allergy Clin Immunol. 2020 Aug;146(2):307-314.e4. doi: 10.1016/j.jaci.2020.06.010. Epub 2020 Jun 15.
6
COVID-19, severe asthma, and biologics.新型冠状病毒肺炎、重度哮喘与生物制剂
Ann Allergy Asthma Immunol. 2020 Sep;125(3):357-359.e1. doi: 10.1016/j.anai.2020.06.012. Epub 2020 Jun 14.
7
COVID-19 in a patient with severe asthma treated with Omalizumab.使用奥马珠单抗治疗的重度哮喘患者中的新型冠状病毒肺炎
Allergy. 2020 Oct;75(10):2705-2708. doi: 10.1111/all.14456. Epub 2020 Jun 27.
8
Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement.COVID-19 大流行时期变应性疾病患者使用生物制剂的相关考虑：一项 EAACI 立场声明。
Allergy. 2020 Nov;75(11):2764-2774. doi: 10.1111/all.14407.
9
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.使用 ISARIC WHO 临床特征协议住院的 20133 例英国新冠患者的特征：前瞻性观察队列研究。
BMJ. 2020 May 22;369:m1985. doi: 10.1136/bmj.m1985.
10
COVID-19, asthma, and biological therapies: What we need to know.新型冠状病毒肺炎、哮喘与生物疗法：我们需要了解的内容。
World Allergy Organ J. 2020 May 16;13(5):100126. doi: 10.1016/j.waojou.2020.100126. eCollection 2020 May.

新型冠状病毒肺炎与重度哮喘中的生物制剂：来自比利时重度哮喘登记处的数据

COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry.

作者信息

Hanon Shane, Brusselle Guy, Deschampheleire Maud, Louis Renaud, Michils Alain, Peché Rudi, Pilette Charles, Rummens Peter, Schuermans Daniel, Simonis Hélène, Vandenplas Olivier, Schleich Florence

机构信息

Respiratory Division, University Hospital UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium

Dept of Respiratory Medicine, Ghent University Hospital, Gent, Belgium.

出版信息

Eur Respir J. 2020 Dec 3;56(6). doi: 10.1183/13993003.02857-2020. Print 2020 Dec.

DOI:10.1183/13993003.02857-2020
PMID:33093115
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7712385/
Abstract

https://bit.ly/3ndZmyD

摘要

这看起来是一个链接，无法直接翻译为中文，其对应的中文表述大概是：https://bit.ly/3ndZmyD（可直接保留英文链接） 。若需对链接指向的内容进行翻译，请提供链接对应的网页文本。